Development and External Validation of Multimodal Machine Learning Models to Predict

High Inpatient Opioid Exposure

Machine Learning Models for High Inpatient Opioid Exposure

Authors and Contributions:

Swara Kale (corresponding author) (B.S.)[a] - Conceptualization; Data curation; Formal analysis;

Investigation; Methodology; Writing - original draft

Dr. Devender Singh (Ph. D)[b] - Supervision; Validation; Writing - review & editing

Dr. Eeric Truumees (MD, attending physician)[b] - Supervision; Validation; Writing - review &

editing

Dr. Matthew Geck (MD, attending physician)[b] - Supervision; Validation; Writing - review &

editing

Dr. John Stokes, MD (MD, attending physician)[b] - Supervision; Validation; Writing - review &

editing

Affiliations:

a - The University of Texas at Austin, 101 E 21st Street, Austin, Texas 78712, United States;

swarak627@gmail.com

b - Ascension Texas Spine and Scoliosis, 1004 W 32nd St #200, Austin, TX 78705, United States;

ABSTRACT

High inpatient opioid exposure is associated with increased risk of persistent opioid use, yet early identification of high-risk patients during hospitalization remains limited. We developed and evaluated machine learning models to predict extreme opioid exposure using electronic health record data from MIMIC-IV. This retrospective cohort-based prediction modeling study included 223,452 unique first hospital admissions. The outcome was extreme opioid exposure, defined as the top decile of morphine milligram equivalents (MME) per day among opioid-exposed admissions (corresponding to ≥225 MME/day in the development cohort), representing 2.65% of all admissions.

Structured early-admission features included demographics, admission characteristics, laboratory utilization and abnormality summaries, and 24-hour procedural indicators. Discharge-note data were incorporated using ClinicalBERT embeddings and bigram features. Models were trained using an 80/10/10 split, with temporal validation performed on the most recent 10% of admissions. External validation was conducted using the MIMIC-III and eICU Collaborative Research Database cohorts. Performance was assessed using ROC-AUC and PR-AUC with 95% confidence intervals.

Among structured-only models, XGBoost achieved the best internal test performance (ROC-AUC 0.932 [0.924-0.940]; PR-AUC 0.223 [0.193-0.262]). A combined structured and notes model improved precision-recall performance (ROC-AUC 0.932 [0.920-0.943]; PR-AUC 0.276 [0.229-0.331]). Temporal validation showed similar discrimination (ROC-AUC 0.929; PR-AUC 0.223).

In external validation, performance decreased substantially. In MIMIC-III, the model achieved

ROC-AUC 0.669 [0.659-0.680] and PR-AUC 0.018 [0.017-0.019], while in eICU performance was

further attenuated (ROC-AUC 0.567 [0.556-0.576]; PR-AUC 0.018 [0.017-0.019]). Predicted

probabilities were poorly calibrated in both external datasets, with limited correspondence

between predicted and observed risk.

These findings demonstrate that while EHR-based machine learning models can achieve strong

internal discrimination, their performance and calibration may degrade substantially across

independent healthcare systems -- underscoring the need for dataset-specific validation and

recalibration prior to clinical application.

AUTHOR SUMMARY

Opioid medications are commonly used in hospitals to treat pain, but some patients receive

very high doses, which may increase their risk of long-term opioid use and dependence.

Identifying these high-risk patients early during hospitalization could help doctors make safer

prescribing decisions and improve pain management.

In this study, we analyzed electronic health record data from over 220,000 hospital admissions

to develop machine learning models that estimate which patients are likely to receive high

levels of opioids. We focused on information available within the first 24 hours of admission,

including patient characteristics, laboratory testing patterns, and procedures. We also

examined whether information from clinical notes could improve predictions.

We found that the models performed well within the original dataset, and that combining

structured data with clinical notes improved performance. The patterns identified by the

models -- such as links to surgical procedures and more intensive care -- were in line with

expectations. However, when the models were tested in different hospital datasets,

performance declined, and predicted risks no longer matched what actually happened to

patients.

These findings highlight an important challenge in applying machine learning in healthcare:

models that perform well in one setting may not work reliably in others. While routinely

collected hospital data may help identify patients at risk early, predictive models must be

carefully tested and adapted before they can be safely used in new clinical environments.

INTRODUCTION

Opioid use has been a critical public health concern in the United States for the past 30

years.[1, 2] Although overdose deaths have decreased in recent years, more than 68,000

individuals died from drug overdose between September 2024 and September 2025.[3, 4]

Opioids may be obtained illicitly or through legitimate prescriptions. Among prescription

medications, opioids remain the most frequently misused class, with more than 7.6 million

prescription users transitioning to misuse annually.[5] In 2023 alone, 13,026 individuals died

from prescription opioid overdose.[6]

Opioid administration during hospitalization is common, particularly following major surgical

procedures and other high-intensity interventions.[7, 8] While short-term opioid therapy is

often clinically necessary for acute pain management, accumulating evidence indicates that

inpatient opioid exposure may increase the likelihood of persistent opioid use after discharge

and elevate the risk of long-term dependence or misuse.[9-11] Additionally, substantial

variability exists in inpatient opioid prescribing intensity across geographic regions, institutions,

and individual prescribers, even among patients with comparable clinical presentations.[12-14]

This heterogeneity suggests that factors beyond clinical necessity contribute to high-dose

exposure, with some hospitalizations experiencing disproportionately intense opioid

administration.

Existing efforts to mitigate opioid-related harm have largely focused on outpatient prescribing

practices, prescription drug monitoring programs, and community-level interventions.[15]

Comparatively less attention has been directed toward identifying patients at risk for extreme

opioid exposure during hospitalization, despite the hospital setting representing a critical and

potentially modifiable point of care. A predictive model capable of identifying hospitalizations

at risk for unusually high opioid dosing could enable targeted stewardship and earlier clinical

review.

In this study, we developed, internally validated, and externally evaluated machine learning

models to predict extreme inpatient opioid exposure using electronic health record (EHR) data.

Extreme exposure was defined as the top decile of morphine milligram equivalents (MME) per

hospital day among opioid-exposed admissions. Our primary structured model incorporated

demographic, diagnostic, procedural, laboratory, and medication-derived features available

early in hospitalization to estimate the probability of unusually high opioid intensity.

We additionally evaluated a notes-only model trained on clinical documentation to determine

whether unstructured text independently contains predictive signals associated with opioid

intensity. Furthermore, we constructed a multimodal model integrating structured features

with note-derived embeddings to assess whether combining quantitative data with clinical

language improved predictive performance. Exploratory analysis of clinical text was performed

to provide interpretability of text-derived signals.

Finally, we evaluated model generalizability through external validation in independent

datasets. Differences in patient populations, documentation practices, and data structure

across healthcare systems may substantially impact model performance. By systematically

comparing structured, text-based, and multimodal approaches, we aimed to examine how

model discrimination and calibration change across heterogeneous clinical settings and to

assess the extent to which predictive performance translates beyond the development dataset.

RESULTS

Participants and Cohort Characteristics:

A total of 546,028 hospital admission records were screened, of which 223,452 unique first

admissions met eligibility criteria and were included in the final analytic cohort. Among these

admissions, 4,627 (2.65%) met criteria for high-risk opioid exposure, defined as the top decile of

daily morphine milligram equivalents (MME) among opioid-exposed admissions (corresponding

to ≥225 mg/day in the development cohort). Overall, 59,441 admissions (26.5%) received any

opioid exposure during hospitalization. The distribution of MME per day among opioid-exposed

admissions was right-skewed (median 54.7; IQR 19.5-122.1).

Admissions were randomly assigned into training (n = 178,762; 3,730 events), validation (n =

22,345; 465 events), and test (n = 22,345; 432 events) sets, with stable outcome prevalence

across splits (training: 2.09%; validation: 2.08%; test: 1.94%).

Baseline characteristics stratified by outcome status are shown in Supplementary Table 1.

Compared with non-top-decile admissions, high-risk admissions were younger and had higher

laboratory utilization within 24 hours. Medication administrations within 24 hours were

substantially higher in the high-risk group, and surgical admissions were more frequent among

high-risk cases.

Missing Data and Feature Processing:

Medication and laboratory features had moderate missingness, which was addressed using

indicator variables and imputation. No residual missing values remained after preprocessing.

Model Development and Evaluation:

Structured prediction models were developed using ridge logistic regression, random forest,

and extreme gradient boosting. Models were trained on the training set, tuned using the

validation set, and evaluated in the test set.

Model outputs were predicted probabilities of high-risk opioid exposure, and classification

thresholds were selected using the Youden index in the validation set. Primary performance

metrics are summarized in Table 1. Threshold-dependent performance metrics are provided in

Supplementary Table 2.

Table 1: Primary model performance

Dataset	Model	ROC-AUC (95% CI)	PR-AUC (95% CI)	Brier (95% CI)	Calibration intercept	Calibration slope
Validation	Ridge logistic	0.892	0.166	0.0187	—	—
Validation	Random forest	0.909	0.201	0.0181	—	—
Validation	XGBoost	0.918	0.216	0.0180	—	—
Validation	Notes-only	0.865	0.150	0.0196	—	—
Validation	Combined	0.933	0.262	0.0179	—	—
Test	Ridge logistic	0.915 (0.903-0.925)	0.185 (0.159-0.217)	0.0172 (0.0158-0.0188)	0.446	1.183
Test	Random forest	0.919 (0.909-0.928)	0.204 (0.174-0.240)	0.0169 (0.0155-0.0184)	0.083	1.094
Test	XGBoost	0.932 (0.924-0.940)	0.223 (0.193-0.262)	0.0166 (0.0152-0.0181)	0.123	1.063
Test	Notes-only	0.861 (0.840-0.881)	0.168 (0.134-0.208)	0.0189 (0.0169-0.0210)	-0.028	0.994
Test	Combined	0.932 (0.920-0.943)	0.276 (0.229-0.331)	0.0173 (0.0155-0.0191)	0.036	1.023

External (MIMIC-III)	XGBoost	0.669 (0.659-0.680)	0.018 (0.017-0.019)	0.0372 (0.0359-0.0388)	—	—
External (eICU)	XGBoost	0.567 (0.556-0.576)	0.018 (0.017-0.019)	0.0192 (0.0187-0.0197)	—	—

Model Performance: Structured-Only Models

148 In the independent test cohort, XGBoost achieved the best performance among structured

149 models, with ROC-AUC 0.932 [0.924-0.940] and PR-AUC 0.223 [0.193-0.262], and demonstrated

150 good internal calibration (slope 1.06; intercept 0.12). Random forest and ridge logistic

151 regression showed slightly lower discrimination. Bootstrap resampling confirmed stability of

152 performance estimates (Table 1) (Fig 1).

Model Interpretation: SHAP Analysis

154 SHAP analysis of the XGBoost model indicated that early inpatient utilization features were the

155 strongest contributors to predicted risk, particularly medication event counts, age, and surgical

156 status (Fig 2).

Notes-Only Model and Multimodal Integration:

Embeddings were available for 58.4% of admissions. The notes-only model achieved ROC-AUC

0.861 and PR-AUC 0.168 in the test subset. The combined structured + notes model improved

performance (ROC-AUC 0.932; PR-AUC 0.276), representing substantial enrichment over

baseline prevalence (Table 1) (Fig 3). However, because discharge summaries are generated

after hospitalization, these findings reflect retrospective signal capture rather than prospective

prediction.

Contrastive Text Analysis:

Bigram analysis identified phrases enriched among high-risk admissions, including terms related

to orthopedic and spine procedures (Supplementary Table 3) (Fig 4).

Subgroup Performance:

Model performance remained stable across surgical and non-surgical admissions, with

differences in PR-AUC reflecting underlying outcome prevalence. Calibration remained stable

across subgroups (Supplementary Table 4) (Fig 5).

Temporal Validation:

To assess temporal generalizability, we evaluated model performance in a temporally held-out

cohort. In this cohort, XGBoost achieved ROC-AUC 0.929 and PR-AUC 0.223. Performance was

similar to that observed in the primary test cohort (Table 1) (Fig 6).

External Validation:

In external validation, model performance decreased substantially compared with internal and

temporal evaluation. In the MIMIC-III cohort (n = 46,476; outcome prevalence 2.6%), the model

achieved a ROC-AUC of 0.669 [0.659-0.680] and PR-AUC of 0.018 [0.017-0.019]. In the eICU

cohort (n = 200,859; outcome prevalence 1.6%), discrimination was further attenuated, with

ROC-AUC 0.567 [0.556-0.576] and PR-AUC 0.018 [0.017-0.019] approaching near-random

discrimination (Table 1) (Fig 7). This represents a reduction in ROC-AUC of approximately 0.36

compared with internal test performance.

External calibration analysis demonstrated substantial degradation in predicted probability

reliability in both external datasets. In MIMIC-III, predicted probabilities showed weak and non-

monotonic association with observed outcomes, while in eICU, predicted risks exhibited

minimal separation between high- and low-risk admissions. Calibration slopes were markedly

reduced in both datasets, indicating severe distortion in probability scaling. These findings

indicate that, although the model retained modest ranking ability, its probability estimates

were not well calibrated in external settings (Fig 8).

DISCUSSION

In this study, we developed and validated machine learning models to identify hospital

admissions at risk for extreme inpatient opioid exposure. Internal model performance

demonstrated strong discrimination and suggested that routinely collected inpatient data

captured broader signals of care complexity associated with high opioid exposure. However,

this performance did not generalize to external datasets, where both discrimination and

probability calibration declined substantially.

In clinical practice, hospitalized patients generate multimodal data streams. Structured data

quantify measurable aspects of care, such as laboratory utilization, procedural burden, and

medication administration, while unstructured notes capture physician interpretation,

procedural narratives, and contextual detail surrounding the patient's clinical course. These

modalities represent complementary views of the same hospitalization. Our results suggest

that structured utilization patterns provide a strong foundation for identifying high-intensity

opioid exposure, while narrative documentation contributes additional context in specific

settings, particularly surgical admissions.

Extreme opioid exposure was uncommon but clinically meaningful, occurring in a small minority

of admissions. These cases were characterized by greater early laboratory utilization, higher

medication event counts, and more frequent surgical procedures. Such patterns likely reflect

more complex operative courses, trauma-related admissions, or high-acuity postoperative care

-- contexts in which aggressive analgesia may be required.[16] Importantly, the model did not

rely on opioid-specific inputs alone but instead captured broader signals of clinical intensity.

This suggests that extreme dosing may be predictable from overall care trajectories rather than

from pain management variables in isolation.

Subgroup analyses further illustrate how clinical context shapes predictive signals. Structured

models demonstrated stable discrimination across surgical and non-surgical admissions,

indicating that utilization-based features generalize across heterogeneous inpatient

populations. In contrast, the notes-only model performed more strongly in surgical contexts

and less consistently in non-surgical admissions. Surgical discharge summaries often contain

detailed procedural narratives, implant descriptions, and postoperative plans, which may

encode implicit signals of anticipated analgesic need. Medical admissions, by comparison, may

contain more templated or symptom-focused language, potentially limiting the strength of

narrative-based prediction. The improved performance observed with multimodal integration

suggests that quantitative measures and clinician documentation capture partially distinct

aspects of care complexity.

Bigram analysis of discharge notes supports the clinical plausibility of the learned narrative

signals. Terms enriched among high-risk admissions were predominantly related to orthopedic,

trauma, and spine procedures, such as "external fixation" and "laminectomy fusion". These

clinical scenarios are commonly associated with substantial postoperative pain and extended

analgesic requirements and have been previously linked to postoperative opioid

prescribing.[17] Conversely, phrases enriched among low-risk admissions reflected general

review-of-systems language or laboratory descriptors.

Temporal validation demonstrated that model performance remained stable when applied to

more recent admissions, suggesting that the predictive relationships identified were not limited

to a specific time period. Although prescribing behaviors and stewardship efforts continue to

evolve nationally, the model's relative stability across time supports the hypothesis that

extreme opioid exposure reflects persistent underlying drivers of care intensity rather than

transient prescribing variation.[18]

External validation revealed a marked and clinically meaningful decline in model performance,

highlighting limited transportability across independent datasets. This degradation likely

reflects multiple forms of dataset shift, including differences in patient case variety, clinical

practice patterns, feature availability, and data representation. For example, variation in

medication documentation, laboratory reference ranges, and procedural coding required

feature harmonization using proxy variables, potentially attenuating predictive signal.

Additionally, differences in outcome prevalence and the use of dataset-specific percentile

thresholds may have introduced label distribution shifts that further impacted performance.

Together, these results demonstrate limited transportability of the model across datasets and

suggest that predictive performance is highly sensitive to differences in patient populations,

feature representation, and prescribing practices. The relatively higher performance observed

in MIMIC-III compared with eICU suggests partial generalizability across temporally distinct but

structurally similar datasets, but poor generalization across more heterogeneous healthcare

systems.

These findings suggest that a substantial portion of model performance in the development

cohort may be driven by dataset-specific patterns rather than fully generalizable relationships.

As a result, direct deployment of such models without recalibration may lead to inaccurate risk

estimation in new clinical environments.

Methodologically, these results emphasize the importance of rigorous external validation in

EHR-based machine learning studies. Models trained on a single dataset may overestimate

performance due to implicit encoding of local practice patterns, documentation structures, and

patient population characteristics. Future work should focus on domain adaptation, feature

standardization, and recalibration strategies to improve generalizability across institutions.

From a clinical perspective, identifying admissions at risk for extreme opioid exposure has

several potential applications. Because high inpatient dosing has been associated with

downstream opioid use, persistent exposure, and increased healthcare utilization, early

identification may represent a modifiable intervention point.[19] Operationally, a model could

be deployed at the 24-hour mark following admission, once early clinical data was available.

This timepoint provides an opportunity to reassess analgesic strategies, optimize multimodal

pain management, or involve specialty consultation. Given the low outcome prevalence, risk

thresholds could be selected to flag only the highest-risk patients, thereby limiting alert burden

while focusing attention on those most likely to experience extreme exposure. Potential future

integration into clinical decision support systems could enable automated notification to care

teams or pharmacy services. Importantly, predicted risk should support clinical judgment and

proactive planning rather than mandate opioid restriction.

Additionally, opioid prescribing patterns vary across patient demographic

characteristics.[20,21] Because predictive models may inadvertently reflect underlying practice

patterns, careful evaluation across demographic subgroups is essential prior to clinical

deployment. Future work should assess subgroup discrimination, calibration, and threshold

performance to ensure equitable implementation and to avoid amplifying existing disparities in

opioid prescribing, particularly among female patients and individuals from racial and ethnic

minority backgrounds.

Limitations:

This study has several limitations. First, although external validation was performed using

MIMIC-III and the eICU Collaborative Research Database, model performance declined

compared with internal and temporal validation, reflecting challenges in transportability across

datasets with differing patient populations, feature availability, and prescribing practices.

Second, discharge note embeddings were available for only a subset of admissions, introducing

potential selection bias related to documentation availability and limiting generalizability of

text-based models. Third, extreme opioid exposure was defined using a relative, dataset-

specific threshold (top decile among opioid-exposed admissions), which may limit direct

comparability across datasets and require recalibration in settings with different prescribing

distributions. This approach also contributed to differences in outcome definition across

external cohorts. Fourth, key clinical and contextual factors, including pain severity,

intraoperative management, and provider-level prescribing behaviors, were not captured in the

available data, potentially limiting model interpretability and performance. Finally, the low

prevalence of extreme exposure limits positive predictive value, indicating that these models

are best suited for risk stratification rather than definitive clinical decision-making.

MATERIALS AND METHODS

Data Source and Study Setting:

We conducted a retrospective cohort study using MIMIC-IV for the development and validation

of prediction models. MIMIC-IV is a publicly available, de-identified electronic health record

(EHR) database comprising detailed clinical data from patients admitted to Beth Israel

Deaconess Medical Center, a large tertiary academic medical center in Boston,

Massachusetts.[22-24] The MIMIC-IV hospital module contains structured clinical data from

223,452 unique patients between 2008 and 2022, including demographic characteristics,

laboratory measurements, procedures, medication administrations, and admission-level

encounter data.

Free-text clinical documentation was obtained from the MIMIC-IV-Note module, which includes

331,793 de-identified discharge summaries from 145,915 patients during the same study

period.[25] Discharge summaries were linked to structured admission-level data using the

unique hospital admission identifier.

Study Population:

All inpatient hospital admissions recorded in the MIMIC-IV hospital module during the study

period were eligible for inclusion. To avoid correlated observations from repeat

hospitalizations, only the first hospital admission per patient was included in the analysis. No

age-based exclusions were applied. The cohort was partitioned into training, validation, and

test sets for model development, with temporal validation performed as a secondary analysis.

Outcome Definition:

The primary outcome was extreme inpatient opioid exposure within the first 24 hours of

hospital admission. Opioid exposure was quantified as the total morphine milligram equivalents

(MME) administered during this period, calculated using standardized equianalgesic conversion

factors.[26]

Among admissions receiving any opioid within 24 hours (MME > 0), total MME values were

ranked, and the 90th percentile was used to define extreme exposure. This threshold was

calculated using the full cohort prior to model development and applied unchanged across all

data partitions. Because this approach yields dataset-specific absolute thresholds, direct

comparability across external datasets may be limited.

Predictor Variables:

Predictor domains included demographic characteristics, laboratory utilization metrics,

procedure indicators, and non-opioid medication administration counts. Demographic variables

included age, sex, race, marital status, insurance type, primary language, admission type,

admission location, calendar year of admission, and a categorical year grouping variable.

Laboratory-related predictors included the total number of laboratory events within 24 hours,

the number of laboratories with reference ranges available, counts of abnormal laboratory

values (overall, low, and high), and the proportion of abnormal laboratory results. Procedure-

related predictors included binary indicators for major procedural categories occurring within

the first 24 hours (spine, orthopedic, neurologic, cardiac, abdominal, and vascular procedures),

a composite indicator for any procedure, total procedure count, and a surgical admission flag.

Medication-related predictors explicitly excluded opioid administrations and opioid-derived

features. Variables directly representing opioid dose or opioid administration counts were

excluded from predictors. In secondary analyses, free-text discharge summaries were used to

construct text-based predictors. As discharge summaries are authored after hospitalization and

may contain post-exposure information, text-based models were evaluated as retrospective

comparators rather than real-time early prediction tools.

Data Preprocessing and Feature Engineering:

All preprocessing steps were performed after partitioning the dataset into training, validation,

and test sets. Structured predictors were derived from data available within the first 24 hours

of admission and aggregated at the admission level.

Laboratory-related variables were treated as structurally zero when no laboratory values were

recorded during the 24-hour window. Indicator variables were created to denote admissions

with no laboratory measurements and no laboratory results with reference ranges.

For remaining numeric predictors, missing values were imputed using median imputation.

Median imputation values were derived from the training dataset and applied unchanged to

validation and test sets.

Categorical predictors were encoded as factor variables. Missing or empty categorical values

were assigned to a separate "Unknown" category. Factor levels were defined using the training

dataset and applied consistently to validation and test datasets to ensure alignment across

partitions.

All analyses were conducted in R (version 4.4.2) and Python (version 3.12.10) using ranger,

glmnet, xgboost, and HuggingFace Transformers libraries.[28-32]

Discharge Notes Preprocessing:

Text representations were generated using a pretrained ClinicalBERT model, a domain-adapted

transformer model trained on clinical text.[33] Embeddings for validation and test sets were

generated without exposure to outcome labels and without updating model weights.

A front-back truncation strategy was applied. For each note, two tokenized segments were

generated: 1) the first 256 tokens of the note (front segment) and 2) the last 256 tokens of the

note (back segment).

Each segment was independently processed using ClinicalBERT, and the embedding

corresponding to the [CLS] token was extracted as a 768-dimensional representation. Front and

back embeddings were concatenated to produce a 1,536-dimensional vector for each

admission-level note. Resulting embeddings were merged with structured admission-level

predictors for downstream modeling.

Data Partitioning:

The cohort was randomly partitioned into training (80%), validation (10%), and test (10%) sets

using stratified sampling to preserve outcome prevalence across partitions. The validation set

was used for hyperparameter tuning and model selection. The test set was held out and used

exclusively for final performance evaluation. The random stratified split served as the primary

evaluation framework, with temporal validation conducted as a secondary analysis to assess

robustness to distributional shift.

Models:

Three model classes were evaluated for structured predictors: random forest, penalized logistic

regression, and gradient boosting. For text-only models, admission-level ClinicalBERT

embeddings were used as predictors in a ridge-regularized logistic regression model. For

combined models, structured predictors and text embeddings were concatenated and modeled

using ridge-regularized logistic regression to stabilize estimation in the presence of high-

dimensional features and to reduce overfitting. The XGBoost model was selected as the primary

model for external validation based on internal performance.

Hyperparameter Tuning:

Random forest models were trained using the ranger implementation with 500 trees. Class

imbalance was addressed using inverse-prevalence class weights computed from the training

data. The regularization parameter (λ) for ridge-regularized logistic regression models was

selected using 5-fold cross-validation. For gradient boosting models, hyperparameters were

tuned using the validation set, including learning rate, tree depth, subsampling, and column

sampling, with early stopping based on validation ROC-AUC. For text-only and combined

models, ridge regularization was selected via cross-validation on the training set.

Model Evaluation:

Model performance was evaluated on the held-out test set. Discrimination was assessed using

the area under the receiver operating characteristic curve (ROC-AUC) and the area under the

precision-recall curve (PR-AUC), the latter included given the relatively low prevalence of the

outcome. 95% confidence intervals were estimated using nonparametric bootstrapping with

2,000 resamples of the test set.

Overall prediction error was quantified using the Brier score. Calibration in external datasets

was assessed using calibration curves and calibration slope and intercept.

Model Interpretation:

To characterize feature contributions, SHAP values were computed for the XGBoost model to

quantify the relative importance and directionality of individual predictors in relation to high

opioid exposure.[34]

Subgroup Analysis:

To evaluate performance across clinically distinct admission types, analyses were conducted for

global, surgical, and non-surgical cohorts. A binary surgical admission flag was derived using

International Classification of Diseases (ICD) procedure codes recorded for each hospital

admission.[35, 36] Using the surgical flag, separate models were trained and evaluated within

the surgical-only and non-surgical-only cohorts. The original global exposure threshold was

retained for subgroup analyses. The same modeling pipeline, hyperparameter selection

strategy, and evaluation framework described for the global models were applied to each

subgroup. For each subgroup, discrimination, calibration, and clinical utility metrics were

reported using the same procedures applied to the full cohort.

Temporal Validation:

To evaluate robustness to temporal dataset shift, a time-based split was performed using

admission timestamp, with the most recent 10% of admissions reserved as a temporally held-

out test cohort. Imputation parameters, categorical level definitions, and any high-cardinality

category handling were derived from the temporal training set and applied unchanged to the

temporal validation and test sets to prevent information leakage.

Random forest, ridge-regularized logistic regression, and XGBoost models were retrained using

the temporal training set. Hyperparameter selection and early stopping procedures mirrored

those used in the primary random split analysis. Final performance was evaluated on the

temporal test set (latest 10% of admissions) using matching discrimination and calibration

metrics.

Contrastive Text Analysis:

Exploratory contrastive text analysis was performed on discharge summaries to identify

language patterns associated with high versus low opioid exposure. Discharge notes were

tokenized and converted into bigrams. Tokens were restricted to alphabetic words 3-25

characters in length, with standard English stopwords and a curated set of clinical stopwords

removed. Repeated-word bigrams were excluded, as were bigrams occurring fewer than 100

times overall. For each retained bigram, a log-odds ratio with Dirichlet smoothing was

computed to quantify enrichment in high- versus low-opioid groups.

External Validation:

To evaluate model generalizability across independent datasets, external validation was

performed using the MIMIC-III and eICU Collaborative Research Database cohorts.[37-40]

For MIMIC-III, an ICU-based cohort was constructed using first ICU stays per patient. The final

cohort included 46,476 ICU admissions, with an outcome prevalence of 2.6% (n = 1,207). For

eICU, we utilized the multicenter ICU cohort comprising 200,859 admissions across diverse

hospital systems, with an outcome prevalence of 1.6% (n = 3,218).

Predictor variables for external validation were derived using data available within the first 24

hours of ICU admission, consistent with the feature definitions used in the MIMIC-IV

development cohort. Due to differences in database structure and variable availability,

predictors were harmonized across datasets using analogous data elements where direct

equivalents were unavailable. Laboratory features were derived from 24-hour lab records as

counts of measurements and abnormal values, with abnormality defined using available flags in

MIMIC-III and approximated using total lab counts in eICU. Medication features were

constructed using administration records and counts of opioid-related medication events within

the first 24 hours were used as proxies for treatment intensity. Procedure-related features

were derived from procedure and treatment tables, including counts of procedures and binary

indicators of any procedure within 24 hours. A surgical admission flag was defined based on the

presence of procedure codes in MIMIC-III and approximated in eICU using admission diagnosis

text.

The primary outcome, extreme opioid exposure within 24 hours, was defined independently

within each dataset using the same percentile-based approach as in the development cohort.

Among admissions receiving any opioid within the first 24 hours, the top decile of total MME

was used to define extreme exposure, ensuring consistency in relative outcome definition,

while allowing absolute exposure thresholds to vary across datasets.

The final XGBoost model trained on the MIMIC-IV development cohort was applied directly to

external datasets without retraining. No model recalibration was performed prior to external

evaluation. All preprocessing steps, including median imputation values, categorical level

definitions, and feature encoding schemes, were derived from the MIMIC-IV training data and

applied unchanged to MIMIC-III and eICU to prevent information leakage.

Model performance was evaluated using ROC-AUC and PR-AUC. Confidence intervals were

estimated using nonparametric bootstrapping (B = 500). External validation results were

compared with internal and temporal validation to assess generalizability across datasets.

Acknowledgments: The authors acknowledge the PhysioNet team and the investigators who

contributed to the MIMIC-IV, MIMIC-III, and eICU databases.[22-25][37-40] Authors completed

the required data use training and certification for access.

Competing Interests: The authors declare that they have no known competing financial

interests or personal relationships that could have appeared to influence the work reported in

this paper.

Funding Disclosures: The authors declare that they have no funding disclosures to report.

REFERENCES

1. Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al.

Responding to the opioid crisis in North America and beyond: recommendations of the

Stanford-Lancet Commission. The Lancet. 2022 Feb 5;399(10324):555-604.

doi:10.1016/S0140-6736(21)02252-2.

2. Office USGA. Opioid Crisis: Status of Public Health Emergency Authorities | U.S. GAO

[Internet]. [cited 2026 Feb 18]. Available from: https://www.gao.gov/products/gao-18-

685r

3. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths

decreased? Widespread fentanyl saturation and decreased drug use among key drivers.

The Lancet Regional Health - Americas. 2025 Nov 1;51. doi:10.1016/j.lana.2025.101226

4. Centers for Disease Control and Prevention. Provisional Drug Overdose Data [Internet].

CDC. 2024. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-

data.htm

5. National Center for Drug Abuse Statistics. Prescription Drug Abuse Statistics [Internet].

NCDAS. 2024. Available from: https://drugabusestatistics.org/prescription-drug-abuse-

statistics/

6. National Institute on Drug Abuse. Drug overdose death rates [Internet]. National

Institutes of Health; 2024. Available from: https://nida.nih.gov/research-topics/trends-

statistics/overdose-death-rates

7. Horn R, Hendrix JM, Kramer J. Postoperative pain control. In: *StatPearls*. Treasure

Island (FL): StatPearls Publishing; 2025. Available from: https://www-ncbi-nlm-nih-

gov.ezproxy.lib.utexas.edu/books/NBK544298/

8. Dowell D. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United

States, 2022. MMWR Recomm Rep. 2022;71. doi:10.15585/mmwr.rr7103a1.

9. Arwi GA, Schug SA. Potential for Harm Associated with Discharge Opioids After Hospital

Stay: A Systematic Review. Drugs. 2020 Apr;80(6):573-85. doi:10.1007/s40265-020-

01294-z.

10. Hapca S, Peet L, Gibson C, Harvey A, Forget P. Persistent post-discharge opioid use and

opioid stewardship: A single-centre retrospective cohort study. Br J Pain. 2024

Dec;18(6):497-503. doi:10.1177/20494637241276106.

11. Srivastava D, Hill S, Carty S, Rockett M, Bastable R, Knaggs R, et al. Surgery and opioids:

evidence-based expert consensus guidelines on the perioperative use of opioids in the

United Kingdom. British Journal of Anaesthesia. 2021 Jun 1;126(6):1208-16.

doi:10.1016/j.bja.2021.02.030

12. Lee S, Song W, Bates DW, Urman RD, Zhang P. The recent trend of twin epidemic in the

United States: a 10-year longitudinal cohort study of co-prescriptions of opioids and

stimulants. The Lancet Regional Health - Americas. 2025 Apr 1;44:101030.

doi:10.1016/j.lana.2025.101030

13. Leventhal EL, Nathanson LA, Landry AM. Variations in Opioid Prescribing Behavior by

Physician Training. West J Emerg Med. 2019 May;20(3):428-32.

doi:10.5811/westjem.2019.3.39311.

14. Substantial Variation in Opioid Prescribing Rates among ED Providers in the Same VA

Healthcare Facility - Publication Brief [Internet]. 2019 [cited 2026 Feb 18]. Available

from:

https://www.hsrd.research.va.gov/research/citations/pubbriefs/articles.cfm?RecordID=

975

15. National Academies of Sciences, Engineering, and Medicine, Health and Medicine

Division, Board on Health Sciences Policy, Committee on Pain Management and

Regulatory Strategies to Address Prescription Opioid Abuse. Pain Management and the

Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription

Opioid Use [Internet]. Phillips JK, Ford MA, Bonnie RJ, editors. Washington (DC):

National Academies Press (US); 2017 [cited 2026 Mar 29]. doi: 10.17226/24781

16. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and

prevention. J Pain Res. 2017 Sep 25;10:2287-98. doi:10.2147/JPR.S144066

17. Alessio-Bilowus D, Chua KP, Peahl A, Brummett CM, Gunaseelan V, Bicket MC, et al.

Epidemiology of Opioid Prescribing After Discharge From Surgical Procedures Among

Adults. JAMA Netw Open. 2024 Jun 26;7(6):e2417651.

doi:10.1001/jamanetworkopen.2024.17651

18. Luby AO, Alessio-Bilowus D, Hu HM, Brummett CM, Waljee JF, Bicket MC. Trends in

Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States.

Annals of Surgery. 2025 Mar;281(3):347. doi:10.1097/SLA.0000000000006461

19. Gerlach EB, Plantz MA, Swiatek PR, Wu SA, Arpey N, Fei-Zhang D, et al. The Drivers of

Persistent Opioid Use and Its Impact on Healthcare Utilization After Elective Spine

Surgery. Global Spine Journal. 2024 Mar 1;14(2):370-9.

doi:10.1177/21925682221104731

20. Ly DP. Association of Patient Race and Ethnicity With Differences in Opioid Prescribing

by Primary Care Physicians for Older Adults With New Low Back Pain. JAMA Health

Forum. 2021 Sep 10;2(9):e212333. doi:10.1001/jamahealthforum.2021.2333

21. Yang N, Fang MC, Rambachan A. Sex Disparities in Opioid Prescription and

Administration on a Hospital Medicine Service. J Gen Intern Med. 2024

Nov;39(14):2679-88. doi:10.1007/s11606-024-08814-7

22. Johnson A, Bulgarelli L, Pollard T, Gow B, Moody B, Horng S, Celi L A, Mark R. MIMIC-IV

(version 3.1). PhysioNet. 2024. RRID:SCR_007345. Available

from: https://doi.org/10.13026/kpb9-mt58

23. Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, et al. MIMIC-IV, a

freely accessible electronic health record dataset. Scientific Data. 2023 Jan 3;10(1).

24. Goldberger AL, Amaral LA, Glass L, Hausdorff JM, Ivanov PC, et al. PhysioBank,

PhysioToolkit, and PhysioNet: components of a new research resource for complex

physiologic signals. Circulation. 2000 Jun 13;101(23):E215-20. doi:

10.1161/01.cir.101.23.e215

25. Johnson A, Pollard T, Horng S, Celi L A, Mark R. MIMIC-IV-Note: Deidentified free-text

clinical notes (version 2.2). PhysioNet. 2023. RRID:SCR_007345. doi: 10.13026/1n74-

ne17

26. Adams MCB, Sward KA, Perkins ML, Hurley RW. Standardizing research methods for

opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator. Pain.

2025 Feb 3;166(8):1729-1737. doi: 10.1097/j.pain.0000000000003529

27. Cron DC, Hwang C, Hu HM, Lee JS, Dupree JM, Syrjamaki JD, Chung KC, Brummett CM,

Englesbe MJ, Waljee JF. A statewide comparison of opioid prescribing in teaching

versus nonteaching hospitals. Surgery. 2019 Apr;165(4):825-831. doi:

10.1016/j.surg.2018.10.005. Epub 2018 Nov 26.

28. R Core Team. *R: a language and environment for statistical computing*; 2025 [cited

2026 Mar 29]. Vienna: R Foundation for Statistical Computing [Internet]. Available

from: https://www.R-project.org/

29. Python Software Foundation. *Python* (version 3.12); 2025 [cited 2026 Mar 29].

[Internet]. Available from: https://www.python.org

30. Wright MN, Ziegler A. ranger: a fast implementation of random forests for high

dimensional data in C++ and R. *J Stat Softw*; 2017 Mar 31 [cited 2026 Mar 29];77(1):1-

17. [Internet]. Available from: https://doi.org/10.18637/jss.v077.i01

31. Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models

via coordinate descent. *J Stat Softw*; 2010 Feb 2 [cited 2026 Mar 29];33(1):1-22.

[Internet]. Available from: https://doi.org/10.18637/jss.v033.i01

32. Chen T, He T, Benesty M, Khotilovich V, Tang Y, Cho H, Chen K, Mitchell R, Cano I, Zhou

T, Li M, Xie J, Lin M, Geng Y, Li Y, Yuan J, Cortes D. *xgboost: extreme gradient boosting*;

2026 [cited 2026 Mar 29]. Version 3.3.0.0 [R package]. [Internet]. Available from:

https://github.com/dmlc/xgboost

33. Alsentzer E, Murphy J, Boag W, Weng WH, Jin D, Naumann T, McDermott M. Publicly

available clinical BERT embeddings. In: *Proceedings of the 2nd Clinical Natural Language*

Processing Workshop; 2019 [cited 2026 Mar 29]; Minneapolis, MN, USA. p. 72-78.

[Internet]. Available from: https://aclanthology.org/W19-1909/

34. Lundberg, S.M. and Lee, S.-I. (2017) A Unified Approach to Interpreting Model

Predictions. *Proceedings of the 31st International Conference on Neural Information*

Processing Systems, Long Beach, 4-9 December 2017, 4766-4777.

35. Slee VN. The International Classification of Diseases: ninth revision (ICD-9). Ann Intern

Med. 1978 Mar;88(3):424-6. doi: 10.7326/0003-4819-88-3-424.

36. World Health Organization. The ICD-10 classification of mental and behavioural

disorders. Geneva: World Health Organization; 1993. Available from:

https://www.who.int/classifications/icd/en/

37. Johnson, A., Pollard, T., and Mark, R. (2016) 'MIMIC-III Clinical Database' (version

1.4), *PhysioNet*. RRID:SCR_007345. Available at: https://doi.org/10.13026/C2XW26

38. Johnson, A. E. W., Pollard, T. J., Shen, L., Lehman, L. H., Feng, M., Ghassemi, M., Moody,

B., Szolovits, P., Celi, L. A., & Mark, R. G. (2016). MIMIC-III, a freely accessible critical

care database. Scientific Data, 3, 160035.

39. Pollard, T., Johnson, A., Raffa, J., Celi, L. A., Badawi, O., and Mark, R. (2019) 'eICU

Collaborative Research Database' (version 2.0), *PhysioNet*. RRID:SCR_007345. Available

at: https://doi.org/10.13026/C2WM1R

40. The eICU Collaborative Research Database, a freely available multi-center database for

critical care research. Pollard TJ, Johnson AEW, Raffa JD, Celi LA, Mark RG and Badawi

O. Scientific Data (2018). DOI: http://dx.doi.org/10.1038/sdata.2018.178.

FIGURE CAPTIONS

Fig 1. ROC and PR curves for ridge logistic regression, random forest, and XGBoost models (test

set)

Fig 2. SHAP Summary plot for structured XGBoost model predicting high inpatient opioid

exposure

Fig 3. ROC and PR curves for text-based models (test set)

Fig 4. Contrastive bigrams in discharge notes associated with high versus low inpatient opioid

use

Fig 5. Model discrimination (ROC-AUC, 95% CI) stratified by surgical subgroup

Fig 6. ROC and PR curves for ridge logistic regression, random forest, and XGBoost temporal

validation

Fig 7. ROC and PR curves for MIMIC-III and eICU external validation XGBoost models

Fig 8. Calibration plots for MIMIC-III and eICU external validation

Contrastive bigrams in discharge notes

High vs low inpatient opioid use (log-odds)

Model discrimination by subgroup

Calibration Plot: MIMIC-III

Calibration Plot: eICU